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Abstract: Multimorbidity is associated with use of multiple medicines, increased risk of 
adverse events and treatment conflicts. This study aimed to examine how older patients with 
multimorbidity and clinicians balance the benefits and harms associated with a medication and 
in the presence of competing health outcomes. Interviews were conducted with 15 participants 
aged $65 years with 2 or more chronic conditions. Three clinical scenarios were presented to 
understand patient preference to take a medicine according to i) degree of benefit, ii) type of 
adverse event and impact on daily living and iii) influence of comorbid conditions as competing 
health outcomes. Semi-structured interviews were also conducted with participants (n=15) and 
clinicians (n=5) to understand patient preferences and treatment decisions, in the setting of 
multimorbidity. The median age of participants was 79 years, 55% had 5 or more conditions 
and 47% took 8 or more medicines daily. When the level of benefit of the medicine ranged from 
14% to 70%, 80% of participants chose to take the medicine, but when adverse effects were 
present, this was reduced to 0–33% depending upon impact on daily activities. In the presence 
of competing health outcomes, 13%–26% of patients chose to take the medicine. Two-thirds 
of patients reported that their doctor respects and considers their preferences and discussed 
medication benefits and harms. Interviews with clinicians showed that their overall approach 
to treatment decision-making for older individuals with multimorbidity was based upon 2 main 
factors, the patients’ prognosis and their preferences. The degree of benefit gained was not the 
driver of patients’ preference to take a medicine; rather, this decision was influenced by type and 
severity of adverse effects. Inclusion of patient preferences in the setting of risks and benefits 
of medicines with consideration and prioritization of competing health outcomes may result in 
improved health outcomes for people with multimorbidity.
Keywords: multimorbidity, comorbidity, patient preference, patient decision-making, 
medicines, geriatrics
Introduction
Multimorbidity is common in the older population, and over 60% of those aged 65 years 
and older will have 2 or more chronic conditions.1 Multimorbidity is associated with 
polypharmacy, high prevalence of treatment conflicts and potentially as a consequence, 
increased risk of medicine-related adverse events.2 Treatment conflicts arise when the 
treatment of one condition results in the worsening of another condition present in a 
patient, as a result of medicine–medicine or medicine–disease interactions.3–5 Further, 
the majority of current clinical guidelines fail to provide specific recommendations 
for treatment in the setting of multimorbidity.6,7 This can lead to complex and difficult 
management decisions for both the patients and the clinicians caring for them.8,9
Correspondence: Gillian E Caughey
Quality Use of Medicines and Pharmacy 
research centre, sansom institute for 
Health Research, School of Pharmacy 
and Medical Sciences, University of 
south Australia, gPO Box 2471, Adelaide, 
sA 5001, Australia
Tel +61 8 8302 1749
email gillian.caughey@unisa.edu.au 
Journal name: Patient Preference and Adherence
Article Designation: Original Research
Year: 2017
Volume: 11
Running head verso: Caughey et al
































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





Use of medicines is associated with both benefits and 
harms, and how to balance these is particularly important in 
the setting of multimorbidity and associated use of multiple 
medicines. The treatment of those with multimorbidity 
commonly involves trade-offs in the setting of competing 
health priorities.8,10 As an example, in older patients with 
osteoarthritis (OA), one trade-off typically encountered is 
that they may wish to use a nonsteroidal anti-inflammatory 
drug (NSAID) to relieve their symptoms, at the expense 
of controlling their hypertension or risk of gastrointestinal 
adverse events. Clinicians and patients may consider differ-
ent outcomes when making health-related decisions. Tension 
between therapeutic goals of patients and their health care 
providers is common; in 30% of occasions, the patients’ main 
priority for their health was not in the top 3 of their health 
care providers.11 This discordance was greatest in those with 
multimorbidity or competing demands. Presenting and incor-
porating competing priorities in the decision-making process 
in terms of global health outcomes including survival, quality 
of life, symptom relief and current physical and cognitive 
function, rather than disease-specific outcomes, is particu-
larly important for patients with multimorbidity.12
Adverse events associated with medicine use, even those 
considered “less severe or side effects” are an important 
determinant of a patient’s willingness to commence or con-
tinue with a medication.8,13 A recent study found that older 
persons’ willingness to take a medication for cardiovascular 
disease (CVD) was more related to potential adverse events 
than to potential benefits.13 The incorporation of patients’ 
preferences for treatment into clinical decision-making is 
essential to patient-centered care14 and is particularly per-
tinent in the context of multimorbidity and the presence of 
competing health outcomes. This study aimed to examine 
how older patients with multimorbidity balance the benefits 
and harms associated with a medication, and in the presence 
of competing health outcomes. In addition, the factors that 
clinicians consider when making treatment decisions for this 
particular patient group were examined.
Methods
Study sample
Participants were recruited from 2 Multidisciplinary Ambu-
latory Consulting Service (MACS) clinics at tertiary teach-
ing hospitals from June 2012 to September 2012. The 
MACS clinics are a holistic management model for older 
patients with multiple comorbidities recently discharged 
from hospital and subsequently referred to the MACS 
clinic for outpatient follow-up. The MACS model of 
care is based on a multidisciplinary health care team and 
assessment, with determination of individualized agreed 
evidence-based goals.15 It has been shown to be associated 
with high compliance to clinical guideline recommenda-
tions for all comorbid conditions present, including both 
non-pharmacological and pharmacological recommendations 
and health service utilization.15 Included in the study were 
those patients aged 65 years or older with English proficiency 
and 2 or more chronic conditions. Patients were excluded 
from the study if they had a formal diagnosis of dementia. 
The Human Research Ethics Committees of Royal Adelaide 
Hospital and University of South Australia approved this 
study. All participants included in the study provided written 
informed consent.
Study design and data collection
Participants underwent face-to-face interviews, which were 
conducted by a clinical pharmacist (KT) at the recruitment 
sites. Sociodemographic variables included gender, age, race, 
marital status, education level and living situation. Clinical 
variables including current medications and chronic condi-
tions were determined from a brief medical history in addition 
to patient records (including preadmission questionnaires and 
clinicians’ referral letters to general practitioners [GPs]). To 
assess self-rated health, participants were asked, “In general 
how would you rate your present health?”, with 5 response 
categories (poor, fair, good, very good or excellent). For 
the analyses of specific disease combinations, the responses 
were grouped into 2 categories: i) poor or fair and ii) good, 
very good or excellent. Functional status was assessed using 
instrumental activities of daily living (ADLs), determined 
using the Barthel index, with a range from 0 (dependent) to 
100 (independent).16
Using similar methodology to a previous study from the 
US, we examined the use of medication for prevention of 
CVD (namely myocardial infarction [MI]) to understand 
patient preferences in our study.13 CVD is highly prevalent in 
the older Australian population and contributes to more than 
50% of the overall burden of disease in the older population.17 
The primary outcome for the study was participants’ prefer-
ence to take a medication to prevent MI when differing levels 
of benefits and risks of medications were presented. The 
benefits of the medication were presented to participants in 
terms of a patient’s baseline risk of MI, with and without the 
medication. In each scenario, patients were asked whether 
they would take the medication with the following response 
categories: “yes”, “no” and “not sure”. Scenarios were com-
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Treatment preferences in older patients with multimorbidity
to facilitate understanding of the benefit/risk information 
presented.18
In the first series of questions, the patients’ baseline risk 
of MI as well as the relative risk reduction (RRR) with medi-
cation varied to determine the influence of varying levels of 
benefit on patients’ willingness to take the medication. To 
understand the influence of benefit alone on patient prefer-
ence to take the medication, in this set of scenarios, the 
medication was said to be free of adverse effects. The level of 
baseline risk of MI varied as did the level of benefit associated 
with taking the medicine. The initial baseline risk of MI was 
1 in 5 (20%) which was derived from the Framingham Heart 
Study19 as previously described.13 Consistent with the average 
absolute risk reduction found in clinical trials assessing the 
use of antihypertensives and statins for primary prevention of 
CVD,20,21 pharmacological intervention was said to provide 
a 30% RRR, decreasing the 5-year risk of MI to 14 in 100 
(14%).13 The baseline risk of MI ranged from 1 in 10 (10%) 
to 4 in 10 (40%), and the risk of MI with the medication 
ranged from 10% to 70%.
In order to assess the influence of adverse events on patient 
preference to take a medication, patients were presented with 
scenarios in which medication use was associated with dif-
fering adverse effects that either did not or did impact on 
daily activities.13 Adverse effects included daily fatigue and 
weakness, daily nausea or daily dizziness and headache, and 
were identified as common adverse effects associated with 
cardiovascular medications from the Australian Medicines 
Handbook.22 The baseline risk in these scenarios as well as 
the RRR with medication remained constant; the baseline MI 
risk was 20%, and the medication reduced the risk to 14%.
We also examined the influence of competing health 
outcomes on patient preferences for treatment. OA and 
chronic respiratory disease are common comorbid conditions 
in older patients with CVD, which are associated with 
treatment conflicts and are competing health priorities.4 The 
use of NSAIDs and corticosteroids for OA and respiratory 
disease, respectively, is detrimental to cardiovascular health, 
with reports of approximately a 10% increase in risk of MI 
being associated with the use of NSAIDs or corticosteroids 
in the older population.23,24 Participants presented with a 
baseline risk of MI of 1 in 5 (20%) and were asked if they 
would be willing to take a medication to relieve joint pain 
for OA, if it increased their risk of MI to 3 in 10 (30%). 
Similarly for respiratory disease, participants presented with 
a baseline risk of MI of 1 in 5 (20%) and were asked if they 
would be willing to take a medication to improve breathing, 
if it increased their risk of MI to 3 in 10 (30%).
Qualitative interviews examining patient 
and clinician views of treatment decisions 
for older patients with multimorbidity
Upon conclusion of the benefit-and-harm scenario interview, 
patients were next asked a series of semi-structured interview 
questions regarding i) treatment preferences, ii) discussion of 
medication adverse effects and iii) shared decision-making. 
The interview guide included open-ended questions based 
on these 3 key topics of interest.
To understand clinician’s views on treatment decisions, 
semi-structured open-ended interview, with questions 
focused on 3 key areas of interest which included i) their 
overall approach to treatment decision-making for older 
patients with multimorbidity, ii) patient preferences and 
iii) polypharmacy, was conducted by the same clinical 
pharmacist (KT) who performed the patient interviews. The 
interview also assessed the influence of patients’ prognosis 
and their preferences on their decision-making.
The interviews were recorded in digital audio format, and 
notes taken throughout the interview to document nonverbal 
communication and context.
Data analysis
Descriptive statistics (proportions, means and standard 
deviations [SDs]) were used to describe the study cohort’s 
sociodemographics and clinical characteristics and patient 
preferences to take medication, under the various scenarios 
presented. For the qualitative studies, the content of each 
interview was transcribed verbatim, and the transcripts were 
then thematically analyzed by 2 independent researchers 
(GEC and KT) to identify key common emerging themes 
using a constant comparison approach.25
Results
A total of 15 patients and 5 clinicians completed the study 
interviews. The patient demographics and clinical charac-
teristics are presented in Table 1. Overall, the presence of 
multiple chronic conditions and medicine use were com-
mon with an average of 6 (±SD 4.3) chronic conditions and 
8 (±SD 3.7) regular prescription medications. All patients 
were taking at least 1 cardiovascular medicine.
Examination of the effect of the degree of benefit 
showed that use of a once-daily medication that was free of 
adverse effects, which provided a 30% RRR to the baseline 
risk of MI (an absolute risk reduction of 6 fewer individuals 
experiencing an MI), resulted in the majority of patients (80%) 
indicating that they would take the medication (Figure 1). 
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a 50% RRR of MI was presented and the proportion of 
patients willing to take the medication decreased. Overall, 
67% responded that they would take the medication, but 
26% of patients presented with this scenario were uncertain 
(Figure 1). In scenario 3 where the baseline risk of MI was 
40%, 80% of patients indicated that they would be willing to 
take a medication free of adverse effects which would provide 
a 75% RRR of MI (Figure 1). In the final scenario presented 
where the baseline risk of MI with the medication was only 
10%, 80% of patients said they would take the particular 
medication even if it provided a 30% decrease in relative 
risk. For all scenarios presented, there was little change in the 
number of patients unwilling to take the medication.
Examination of the effect of harm on patients’ willingness 
to take the medication showed that over 50% of the patients 
examined were not willing to take a medication if it had an 
equivalent degree of benefit and risk (Figure 2). One-half 
reported that they would not take or were unsure whether to 
take a medication if it was associated with mild fatigue and 
weakness that would not impact upon performing ADLs. The 
same result was seen when patients were presented with a 
medication associated with dizziness and headache, but mild 
enough not to impact upon ADL. A larger proportion (67%) 
were unwilling to take or unsure about taking a medication 
with mild nausea as an adverse effect, even if it did not impact 
on ADL (Figure 2).
Of the participants willing to tolerate these mild adverse 
effects, less than a third remained willing if the adverse 
effects were severe enough to interfere with ADL. Fatigue 
and weakness, impacting on ADL, was the least severe of 
the adverse events in this regard, with 33% reporting a will-
ingness to take a medication with this harm profile. Only 
17% of patients were willing to take a medication that 
was associated with dizziness and headache, impacting on 
ADL. By contrast, none of the patients were willing to take 
a medication associated with mild nausea that impacts on 
ADL (Figure 2).
We next examined patient preferences in the context 
of competing health outcomes for use of medications to 
alleviate symptoms associated with common comorbid 
conditions, OA or chronic respiratory disease. In our study 
cohort, 66.7% of the patients had OA, and 26.7% had chronic 
respiratory disease. For OA, 80% of patients would not take 
a medication to relieve joint pain if it was associated with 
a 10% increased risk of MI. By contrast, 54% of patients 
would not take a medication to improve breathing if it would 
increase their risk of MI by 10%, with a greater proportion 
of uncertainty in this context, with 20% unsure of what to 
prioritize (Figure 3).
Qualitative studies focused on patient 
and clinician preferences
Patient interviews
When patients were asked about their perspectives on indi-
vidual patient preferences and shared decision-making, 60% 
(n=9) said they regularly discussed their treatment prefer-
ences with their doctor. Common topics that participants 
said they discussed with their clinicians included rationale 
for treatment, impact of medication on functioning, ability 
of the medication to provide symptomatic relief and the use 
of alternative therapies. However, of these, 22% (n=2) stated 
Table 1 Demographics and clinical characteristics of study 
cohort (n=15)
Patient characteristics Number (%) (unless 
otherwise stated)
Demographics
gender, male 7 (47%)


















Functional status (ADls, Barthel index score)
0–25 (difficulty with ADLs) 0 (0%)
25–50 2 (13%)
50–75 0 (0%)
75–100 (limited/no difficulty with ADLs) 13 (87%)




Average number of chronic conditions (±sD) 6 (±4.26)




Average number of regular prescriptions (±sD) 8 (±3.7)
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Treatment preferences in older patients with multimorbidity
Figure 1 Patient preference to take medication for primary prevention of cardiovascular disease according to degree of benefit only.





















Figure 2 Patient preference to take medication for primary prevention of cardiovascular disease according to type of adverse event and impact on daily activities.








































they would ultimately agree to follow the doctor’s preferred 
approach for treatment, and 22% also stated that they thought 
their doctors did not encourage such discussions. The reasons 
provided by those who did not discuss their treatment prefer-
ences with their doctor included the following: the doctor is 
the expert (n=3) and I trust my doctor (n=2). Overall, almost 
three-quarters of the patients (n=11) felt their doctor respects 
and considers their preferences.
The majority of patients (66%, n=10) recalled that their 
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medications. For the remaining 5 patients, discussions were 
limited to adverse effects of medications only or benefits of 
medications only or no discussion on either the benefits or 
the risks of medications took place.
When questioned about shared decision-making, 
overall, the patient cohort did not desire to have greater 
participation in making health care decisions, with 10 
of the 15 patients stating they feel their preferences and 
opinions are heard and feel content with their current 
physician–patient dynamic. The 5 patients who wished to 
be more involved felt that it would be unrealistic to expect 
greater participation in the complex setting of their care. 
Consideration of patients’ values and beliefs was also 
found to be important. Patients stated they would like to 
be more informed about their condition(s) and the various 
treatment options available.
clinician interviews
Interviews with clinicians showed that their overall approach 
to treatment decision-making for older individuals with 
multimorbidity was based upon 2 main factors: the patients’ 
prognosis and their preferences. These preferences included 
either improving quality of life by relieving patient’s symp-
toms, or decreasing mortality via the use of medications 
to prolong life. Clinicians talked about adapting treatment 
depending upon the patient’s symptoms and not always 
treating to therapeutic targets. Some clinicians mentioned 
prioritizing conditions that were causing the most trouble 
to their patient. The aspect of patient preference was also 
recognized as extremely important due to competing inter-
ests. Clinicians commented that the treatment of younger 
individuals with a single chronic condition is approached 
in a very similar way, reiterating the importance of patient 
preference, but that they can be treated more aggressively. 
On the whole, in younger patients, their general aim was 
to improve mortality as opposed to providing short-term, 
symptomatic relief. Treating younger patients was said to 
be less complex due to the absence of competing health 
outcomes, general use of fewer medications and decreased 
potential for drug interactions.
Clinicians spoke of numerous difficulties when applying 
treatment guidelines for older patients with multiple chronic 
diseases. All mentioned the poor applicability of current 
guidelines to their patients, with several participants noting 
that current guidelines are largely based upon data from 
clinical trials involving younger patients with a single-disease 
state, which is not the reality of most patients that they see. 
As a result, clinicians reported having to juggle several 
treatment guidelines when treating multiple conditions. 
This can lead to discrepancies between treatment targets for 
Figure 3 Patient preference to take medication for common comorbid conditions, osteoarthritis or respiratory disease in the context of competing health outcomes.
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Treatment preferences in older patients with multimorbidity
different conditions, treatment conflicts and polypharmacy. 
Furthermore, physicians appeared frustrated with the guide-
lines because they tend to recommend medications that will 
provide long-term benefits, which was often deemed to be of 
lesser importance for older individuals given their increased 
age and different treatment goals. Again, consideration of 
patient preference and goals for treatment was regarded as 
fundamental to therapeutic guideline applicability. Several 
other factors were said to influence the utilization of clinical 
practice guidelines, including quality of life, social supports, 
functional status, adverse effects and medication adherence 
and accessibility.
Competing health outcomes and polypharmacy were 
common issues faced by the clinicians in this study. When 
dealing with balancing the competing health interests, clini-
cians reported that they tend to base their decisions upon the 
current stage of the disease and its likely progression, while 
incorporating the preferences of the patient. Polypharmacy 
was not viewed as negative when caring for older people 
with multiple conditions as long as it resulted in an overall 
net benefit, with regular medication review and rationaliza-
tion of the treatment regimen. If the medications are causing 
harm, or little or no benefit, then clinicians commented that 
they would suggest the patients to stop or decrease some 
medications. A number of clinicians also mentioned about 
deprescribing; however, some reported difficulties in taking 
this approach. For example 1 participant said that medica-
tions are often restarted by GPs in the community. Another 
reported they commonly found patients to be uncomfort-
able when they were suggested cessation of medication(s). 
The importance of allowing the patient to take control of 
the deprescribing process, to alleviate any anxiety to him/
her, was also highlighted. One physician said that Home 
Medicine Reviews are of great benefit in resolving the issue 
of polypharmacy but expressed frustration in regard to their 
limited accessibility.
Education and communication were the key factors 
identified to reduce the likelihood of adverse effects 
associated with polypharmacy and complex drug regi-
mens. Clinicians spoke of the importance of educating the 
patients and their family/carer, and timely and efficient 
communication between health care providers, namely the 
GP and pharmacist. Apart from minimizing the number of 
prescribed medications, other strategies included asking 
patients about previous adverse drug events, checking 
medication interactions prior to prescribing, avoiding 
complex and predictable drug interactions and regularly 
reviewing drug regimens.
Discussion
In the current study of older patients with multimorbidity, 
the degree of benefit gained from a medicine was not the 
driver of patients’ preference to take the medication. Rather, 
this decision was largely influenced by the type and severity 
of adverse effects associated with the medicine. This was 
further confirmed in the presence of competing health priori-
ties where the use of a medicine for 1 condition may result 
in increased risk of harm associated with another condition. 
We found that the type of competing priority influenced 
therapeutic decisions of patients, illustrating the impact of the 
type of comorbid disease upon patients’ willingness to take 
a medication. Patients were less likely to take a medicine to 
obtain symptomatic relief of joint pain if it increased their risk 
of MI, but were more likely to take a medication to improve 
breathing in respiratory disease with the same risk of MI. 
These results highlight the importance of including patient 
preferences for treatment in the setting of risks and benefits 
of medicines for all conditions present in an individual.
The findings from this Australian study are concordant 
with previous findings where adverse effects of a medicine 
had the greatest influence on patient preferences to take a 
medicine.13,26 Patients’ willingness to take medication was 
relatively insensitive to the benefits associated with therapy. 
In a similar study of 356 patients in the US, where the benefits 
and risks associated with medications for primary CVD pre-
vention were examined as in the current study, between 48% 
and 69% of participants were unwilling to take a medicine if 
it was associated with mild fatigue, nausea or fuzzy think-
ing. If the medication caused adverse effects that affected 
functioning, only 3% would take the medication. This is in 
contrast to 88% of people who responded they would take 
the medicine if it were free of adverse effects.13 In another 
study of patients’ preferences regarding the treatment of knee 
OA, the risk of common medication adverse effects including 
gastrointestinal ulcer had the strongest impact upon patients’ 
choice to take a medicine.26
These findings have numerous implications for the 
development and utilization of clinical treatment guidelines 
for multimorbid patients. Firstly, guideline developers must 
recognize that medication adverse effects are generally 
considered as a competing outcome, independent of their 
severity.13 This is particularly pertinent for older individuals 
with multimorbidity given their use of multiple medications, 
which predisposes them to an increased risk of experiencing 
an adverse event.2 Another important consideration is the 
type of adverse event and the patient’s previous experi-
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the current study. The decision to start a medication should 
be individualized and not solely based upon the benefits 
of the intervention alone. Inclusion of individual patient 
preferences where clinicians are able to tailor their treat-
ment approach to suit the preferences and priorities of their 
patient, while aiming to fulfill their overall therapeutic goal, 
is the key to the provision of patient-centered care.2,27 Com-
munication of risks and benefits of medications, within the 
context of multimorbidity, is an important component, and 
as this study shows, decision-making for patients is highly 
dependent on adverse events, rather than health benefits. 
Compliance with medication regimens for patients with 
chronic diseases is crucial to achieve treatment success 
and is a key challenge for health professionals worldwide.28 
Adverse events and a lack of patient engagement in the 
decision-making process have been identified as contributors 
toward noncompliance.29,30 A better understanding of the 
factors around patients’ willingness to take medications will 
ultimately lead to improved compliance, and may help to 
identify those most at risk of noncompliance and ultimately 
poorer health outcomes.
A number of our findings are consistent with previous 
studies, in regard to decision-making around health care. 
Prior research has concluded that there is significant varia-
tion among patients’ willingness to participate, and many 
patients do not wish to actively participate in prescribing 
decisions. Of those willing to participate, the spectrum of 
involvement ranges from requesting information about 
alternative treatments to enquiring about medication 
adverse effects.2,27 In contrast to previous studies, we found 
that a large proportion of patients reported that their clini-
cian regularly informed them about the benefits and risks 
of therapy prior to treatment initiation. Previous studies 
have reported that physicians do not routinely discuss the 
benefits and risks of medicines, due to time constraints and 
unrealistic patient expectations.9,31,32 It is likely that the 
provision of multidisciplinary collaborative team-based 
care that includes patient preferences and patient goals 
within the MACS model of care facilitated the discus-
sion of medication risks and benefits in this setting. Most 
patients were content with their relationship towards their 
prescriber and did not desire to have a greater influence 
upon the outcome of their health. This theme is common 
among similar studies, with patients’ trust in their doctor 
and their lack of medication knowledge being barriers to 
patient participation.27 From the results obtained, it appears 
that patients who actively contribute to the decision-making 
process may also require additional information regarding 
their therapeutic options. However, despite wishing to 
receive additional information, the majority of patients 
do not want to be involved in health care decisions to a 
greater degree.
The perspective of clinicians regarding overall approach 
to treatment decision-making for older patients with mul-
timorbidity highlights the complexity of caring for these 
patients, in particular the uncertainty of applying disease-
specific guidelines that may not be relevant for older patients 
with multimorbidity or in alignment with patient preferences 
and priorities. While the importance of individual patient’s 
prognosis and treatment goals was deemed fundamental 
in determining the course of treatment for older patients 
with multimorbidity, there was variability in how to best 
incorporate this in the decision-making process. While 
not observed in our study, conflict between clinicians and 
patient goals commonly occurs, and it has been suggested 
that clinicians would benefit from tools to specifically assist 
in shared decision-making, which include approaches to 
reconciling their own and their patients’ priorities.9 Outcomes 
data on treatment strategies in this population and alternative 
guidelines will help to improve decision-making.9 The US 
clinicians have also highlighted the importance of assess-
ing a patient’s function, support networks and evidence of 
prior non-adherence to alleviate issues of polypharmacy and 
complex drug regimens.9
This study had several limitations. The sample size was 
small and reflective of the multimorbid and complex care 
needs of the participants and their current overall health status 
as fair or poor and may not be reflective of the majority of 
older Australians. The general older Australian population 
rate their health as good or above,33 potentially limiting the 
applicability of the findings. Further, we have previously 
shown that the MACS clinic is associated with higher compli-
ance to clinical guideline recommendations for all comorbid 
conditions present, including both non-pharmacological 
and pharmacological recommendations and health service 
utilization,15 and this may also limit applicability to the older 
multimorbid population. While the study was conducted 
at 2 sites, the treating clinicians were the same at both the 
sites. The study questionnaire focused on patients’ willing-
ness to take medication for primary prevention of CVD, and 
how the results obtained relate to other health conditions is 
unclear. The benefit of the medication was presented in terms 
of reduction in the risk of MI, as opposed to the effect on 
universal health outcomes, such as mortality risk, symptom 
relief or functional ability, which may be more applicable 
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Treatment preferences in older patients with multimorbidity
reported that the use of universal health outcomes had limited 
applicability when determining patients’ priority for taking 
a medication.34
Conclusion
This study shows that patients’ willingness to take medica-
tion is not directly influenced by the degree of benefit gained 
from pharmacological intervention. However, the type and 
severity of the adverse effect does significantly influence 
patients’ willingness to take a medication. An increased 
understanding of the treatment decision-making process 
with consideration and prioritization of competing outcomes 
may result in improved health outcomes for individuals with 
multimorbidity.
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